# EDGAR Filing Document

**Accession Number:** 0001840748
**File Stem:** 0001104659-25-073380
**Filing Date:** 2025-8
**Character Count:** 3573
**Document Hash:** 833197862da91cdd6b0d3ab1db222653
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-073380.hdr.sgml**: 20250804

**ACCESSION NUMBER**: 0001104659-25-073380

**CONFORMED SUBMISSION TYPE**: SC14D9C

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250804

**DATE AS OF CHANGE**: 20250804

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LAVA Therapeutics NV
- **CENTRAL INDEX KEY:** 0001840748
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC14D9C
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92425
- **FILM NUMBER:** 251178040

**BUSINESS ADDRESS:**
- **STREET 1:** YALELAAN 62
- **CITY:** UTRECHT
- **STATE:** P7
- **ZIP:** 3584 CM
- **BUSINESS PHONE:** 31 6 3000 3035

**MAIL ADDRESS:**
- **STREET 1:** YALELAAN 62
- **CITY:** UTRECHT
- **STATE:** P7
- **ZIP:** 3584 CM

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LAVA Therapeutics BV
- **DATE OF NAME CHANGE:** 20210115
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LAVA Therapeutics NV
- **CENTRAL INDEX KEY:** 0001840748
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC14D9C

**BUSINESS ADDRESS:**
- **STREET 1:** YALELAAN 62
- **CITY:** UTRECHT
- **STATE:** P7
- **ZIP:** 3584 CM
- **BUSINESS PHONE:** 31 6 3000 3035

**MAIL ADDRESS:**
- **STREET 1:** YALELAAN 62
- **CITY:** UTRECHT
- **STATE:** P7
- **ZIP:** 3584 CM

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LAVA Therapeutics BV
- **DATE OF NAME CHANGE:** 20210115

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 14D-9**

**Solicitation/Recommendation Statement**

**Under Section 14(d)(4) of the Securities Exchange Act of 1934**

**(Amendment No.)**

**LAVA Therapeutics N.V.**

**(Name of Subject Company)**

**LAVA Therapeutics N.V.**

**(Name of Persons Filing Statement)**

**Common shares, nominal value €0.12 per share**

**(Title of Class of Securities)**

**N51517105**

**(CUSIP Number of Class of Securities)**

**Stephen Hurly**

**Chief Executive Officer and President**

**LAVA Therapeutics N.V.**

**Yalelaan 62**

**3584 CM Utrecht, The Netherlands**

**+31 85 016 3100**

**(Name, address, and telephone number of person authorized to receive notices and communications**

**on behalf of the persons filing statement)**

***With a copy to:***

**Divakar Gupta**

**Katie Kazem**

**Courtney T. Thorne** 

**Rita Sobral**

**Cooley LLP**

**55 Hudson Yards**

**New York, New York 10001**

**+1 (212) 479-6000**

⌧ Check the box
 if the filing relates solely to preliminary communications made before the commencement of a tender offer.

This Schedule 14D-9 filing consists of the following communication related to the proposed acquisition of LAVA Therapeutics N.V., a public limited liability company (*naamloze vennootschap*) organized under the laws of The Netherlands (the "Company"), pursuant to the terms of a Share Purchase Agreement, dated as of August 3, 2025, by and among the Company and XOMA Royalty Corporation, a Nevada corporation:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· [Press Release of XOMA Realty Corporation and LAVA Therapeutics N.V. dated August 4, 2025 (Exhibit 99.1)](https://www.sec.gov/Archives/edgar/data/1840748/000110465925073374/tm2522230d1_ex99-1.htm)